Buy the full study
Summary
to understand this market
Detailed content
Inforamtion
- Number of pages : 30 pages
- Format : Digital and PDF versions
- Last update : 12/07/2023
Summary and extracts
1 Market Overview
1.1 Definition and presentation
Antidepressants are medically defined as anything, and especially a drug, used to prevent or treat depression. Available antidepressant drugs include SSRIs or selective serotonin-receptor inhibitors, MAOIs or mono amino oxidase inhibitors, tricyclic antidepressants, tetracyclic antidepressants, and others.
The global antidepressant market is expected to grow from $14.3 billion in 2019 to about $28.6 billion in 2020 as mental health problems are expected to increase due to the COVID-19 pandemic. The market is expected to stabilize and reach $19 billion at a CAGR of 7.4 % through 2023.
Iqvia (a global health information provider) reports a 2.5 % increase in the consumption of antidepressant drugs and a 24 % increase for insomnia and anxiety drugs (in both hospital and pharmacy sales channels) between January and September 2020 compared to the same period in 2019. In addition, 20 % of the population reportedly experienced depressive symptoms during the pandemic (double the incidence of the previous period) indicating a clear connection between lockdown periods and mental health.
According to WHO, 3 million Italians suffer from depression, 1 million of whom have major depression. In addition, the Osmed Report (Aifa) confirms that about 12 million packs of antipsychotics are consumed each year in Italy. These numbers give an idea of the potential of the antidepressant market in this country.
Regarding some of the trends inherent in the Italian market, it is worth noting that there is still a huge disparity between the northern and southern regions of the country regarding the recognition and acceptance of mental illness. indeed, it is possible that these values have also been influenced by stereotypes that have not yet been eradicated in southern regions, which in part delegitimize psychological therapy or discourage many individuals from resorting to it as if it were a sign of weakness or even deviance.
List of charts
- Market size of antidepressants
- Consumption of antidepressants in selected countries
- Composition of spending on antidepressant drugs
- Pharmaceutical exports to total manufacturing
- Main countries by pharmaceutical export
All our studies are available online in PDF format
Take a look at an example of our research on another market!
Latest news
Sanofi plans to spin off its Consumer Healthcare business in 2024 - 28/10/2023
- Year of separate listing of Sanofi's Consumer Healthcare Division: 2024
- Sanofi envisages savings of: up to 2 billion euros between 2024 and the end of 2025
- Presence of Sanofi Consumer Healthcare Division: 150 countries, more than 11,000 employees
Sanofi to spin off its consumer healthcare division and float it on the stock market - 27/10/2023
- Sanofi is a French pharmaceutical company
- The Consumer Healthcare division has over 11,000 employees in 150 countries.
- The demerger of Consumer Healthcare will take place in the fourth quarter of 2024 at the earliest.
- This division accounts for just over 10% of Group sales.
- In 2022, the Consumer Healthcare division generated 5.1 billion euros of Sanofi's 43 billion euros in sales.
- The Consumer Healthcare division posted growth of 13.7% in 2022.
- By 2021, the global consumer healthcare market will be worth over €180 billion.
- The market share of Haleon, the world leader in consumer healthcare, is estimated at 6% in 2021.
- The over-the-counter segment accounts for 90 billion euros, vitamins, minerals and supplements for 50 billion euros, and oral care for almost 30 billion euros.
- Its Dupixent sales approach 11 billion euros in annual sales.
- Beyfortus vaccine is currently marketed in 4 countries, including France.
Sanofi inaugurates Europe's largest vaccine plant at Val-de-Reuil - 07/09/2023
- Sanofi's vaccine plant in Val-de-Reuil celebrated its 50th anniversary.
- Sanofi has invested 250 million euros in two modernization/expansion projects at the plant, which employs 2,200 people.
- It ships 600 million doses of vaccines worldwide every year.
- Sanofi has set up a new influenza vaccine production unit, at a cost of 200 million euros.
- Over the past ten years, Sanofi has invested 600 million euros in Val-de-Reuil.
- Sanofi plans to double sales of its vaccines division between 2018 and 2030, to more than 10 billion euros a year.
Sanofi invests $250 million in flu vaccines in France | Sanofi invests $250 million in flu vaccines in France - 07/09/2023
- Sanofi is the world's fourth-largest vaccines company
- Sanofi invests 250 million euros in its Val-de-Reuil site, Europe's largest vaccine production facility
- Sanofi has 11 vaccine plants
- 50% of Sanofi's production is concentrated in influenza.
- Sanofi increases influenza vaccine production capacity by 40%
- Sanofi's Efluelda vaccine is recommended for the elderly and launched in 18 countries, including 11 where it has been recommended by health authorities.
- Sanofi has invested over 600 million euros in its Val-de-Reuil site over the past ten years.
Sanofi gains a foothold in the obesity market with biotech Adocia - 10/07/2023
- Appetite suppressants derived from antidiabetics are an emerging market
- . Industry giants such as American Lilly and Danish Novo Nordisk are already involved in this market.
- Sanofi paid 10 million for the exclusive right to negotiate a worldwide partnership for Adocia's M1Pram rapid insulin.
- Adocia's M1Pram rapid insulin is special in that it makes you lose weight instead of gaining it.
- The potential market for appetite suppressants derived from antidiabetics is estimated at several tens of billions of dollars a year.
- Sanofi is a specialist in type 1 diabetes, and M1Pram could benefit obese patients suffering from this type of diabetes - around 5% of type 2 diabetics.
- Phase 2 clinical results for M1Pram showed exceptional weight loss with good glycemic control in overweight and obese type 1 diabetics.
- The population that could benefit from M1Pram is estimated at nearly 40 million people worldwide, representing a potential market worth several billion dollars.
Sanofi finally has its Covid-19 vaccine - 13/11/2022
- Doses ready for distribution
- The French laboratory has accepted the dominance of the RNA vaccine and the American Moderna and German BioNTech
- The recombinant protein technology used in its VidPrevtyn Beta will make it possible to vaccinate populations in regions where the cold chain is difficult to maintain
Companies quoted in this study
This study contains a complete overview of the companies in the market, with the latest figures and news for each company. :
Choosing this study means :
Access to more than 35 hours of work
Our studies are the result of over 35 hours of research and analysis. Using our studies allows you to devote more time and added value to your projects.
Benefit from 6 years' experience and over 1,500 industry reports already produced
Our expertise enables us to produce comprehensive studies in all sectors, including niche and emerging markets.
Our know-how and methodology enable us to produce reports that offer unique value for money.
Access to several thousand articles and paid-for data
Businesscoot has access to all the paid economic press as well as exclusive databases to carry out its market research (over 30,000 articles and private sources).
To enhance our research, our analysts also use web indicators (semrush, trends, etc.) to identify market trends and company strategies. (Consult our paying sources)
Guaranteed support after your purchase
A team dedicated to after-sales service, to guarantee you a high level of satisfaction. +44 238 097 0676
A digital format designed for our users
Not only do you have access to a PDF, but also to a digital version designed for our customers. This version gives you access to sources, data in Excel format and graphics. The content of the study can therefore be easily retrieved and adapted for your specific needs.
Our offers :
the antidepressant market | Italy
- What are the figures on the size and growth of the market?
- What is driving the growth of the market and its evolution?
- What is the positioning of companies in the value chain?
- Data from several dozen databases
5 reports pack (-15%) IT Italy
- 5 reports at €75.6 excluding VAT per study to choose from our Italian catalogue for 12 months
- Save 15% on additional studies purchased
- Choose to be refunded any unused credit at the end of the 12-month period (duration of the pack)
See the terms and conditions of the pack and the refund of unused credit.
Our customer references
They have consulted our studies
Discover the opinions (+500)
Malcolm Vincent
Astoria Finance
Gregoire de Castelnau
Stags Participations
Timothé Huignard
PWC
Paul-Alexis Kebabtchieff
BCG
Aymeric Granet
Publicis Consultant
interviews & case studies
All interviews and case studies (45)
